Avalon Pharma
أفالون فارماTechnical Analysis & Signals
Avalon Pharma stock shows a bearish trend with signs of weakness in momentum.
Technical Analysis
The technical analysis of Avalon Pharma stock shows a clear bearish trend, with the current price at SAR 98.25. The Relative Strength Index (RSI) at 36.3 indicates weakness in momentum, suggesting a potential for further decline.
Support & Resistance Levels
The key support level for the stock is at SAR 94.3, while the resistance level is at SAR 101.55. The stock is expected to face difficulty in breaking the resistance level given the current bearish trend.
Volume Analysis
Volume data has not been provided, but a decline in trading volume is expected as the bearish trend continues. A decrease in volume may indicate weakness in momentum and reinforce the likelihood of the current trend persisting.
Fundamental Factors
The price-to-earnings (P/E) ratio stands at 20.3, indicating a relatively high valuation. The dividend yield at 2.45% may attract some investors, but weak financial performance could negatively impact confidence in the stock.
Risk Factors
Potential risks include the continuation of the bearish trend and further loss of momentum. Additionally, general economic conditions in the Saudi market and the TASI index may impact the stock's performance.
Recommendation
Disclaimer: This analysis is for educational purposes only and does not constitute investment advice. Based on current data, it may be wise to closely monitor the stock before making any investment decisions.
Automated analysis is based on historical data and technical indicators and may not reflect future market conditions.
Financial Fundamentals
Price Data
Price Chart - Avalon Pharma
4016Technical Analysis
Moving Averages
Momentum Indicators
Bollinger Bands
Within BandTrend Strength (ADX)
Moderate TrendFinancial Summary
Valuation
- Market Cap
- 1.96B
- P/E Ratio
- 20.30
- P/B Ratio
- 4.70
- EPS (Earnings/Share)
- 4.85
Profitability
- Revenue
- 460.48M
- Net Income
- 97.01M
- Return on Equity (ROE)
- +20.00%
- Shares Outstanding
- 20.00M
Balance Sheet
- Total Assets
- N/A
- Total Debt
- 63.84M
- Debt/Equity
- 0.15
- Free Float %
- +43.1%
Dividends & Margins
- Dividend Yield
- +2.45%
- Dividend/Share
- 2.42
- Book Value
- 20.90
Financial data extracted from published quarterly reports. All values in SAR unless otherwise stated.
Historical Financial Data
2 years| Year | Revenue | Net Income | Total Assets | Total Debt | EPS |
|---|---|---|---|---|---|
| 2024 | 394.00M +16.4% | 79.85M +21.3% | 526.78M +16.4% | 65.48M +5.6% | 3.99 +21.3% |
| 2023 | 338.44M | 65.83M | 452.74M | 62.00M | 3.29 |
Historical data sourced from Yahoo Finance and may differ from official audited financial reports.
Price Forecast
These forecasts are based on technical analysis and AI and do not constitute investment advice. Past performance does not guarantee future results.
News & Events
Avalon Pharma signs agreement with Chinese company to register, market drug in Middle East
Avalon Pharma board recommends 75% capital hike via bonus issue
Avalon Pharma inks MoU with NUPCO for supply continuity
AlJazira Capital issues Q4 2025 profit forecasts
SNB Capital sets Q4 2025 earnings estimates
Key events to drive Saudi-listed firms' performance in Q4 2025
In-depth: Performance of recently-listed TASI firms, key offering indicators since 2024
News source: Argaam (argaam.com)
Dividend History
Dividend data from Tadawul records. All amounts in SAR. Estimated yield calculated based on year-end price.
Ownership Structure
Data source: Yahoo FinanceLast updated: 2026-03-26
Risk Assessment
Risk Factors
Average True Range 4.4% of stock price
Trading volume near or above average
P/E ratio 20.3
Debt-to-equity ratio 0.15
ADX indicator at 25
High volatility and financial pressures requiring careful monitoring
This assessment is automated based on quantitative data and does not constitute investment advice. Please consult a licensed financial advisor before making investment decisions.
FAQ
1 What is Avalon Pharma stock price today?
Avalon Pharma (4016) stock price today is 98.25 SAR, declining by -0.56% compared to the previous session close. The 52-week price range is between 94.30 SAR and 138.40 SAR.
2 What is Avalon Pharma stock valuation?
The automated analysis signal for Avalon Pharma is "Sell" with 65% confidence. The P/E ratio is 20.3. The P/B ratio is 4.70.
3 Is Avalon Pharma Shariah-compliant?
Yes, Avalon Pharma (4016) is Shariah-compliant according to the latest lists approved by relevant Shariah authorities.
4 What are Avalon Pharma dividend distributions?
Avalon Pharma has a dividend yield of 2.45%, with an estimated annual dividend of 2.42 SAR per share.
5 What is Avalon Pharma weekly performance?
Avalon Pharma performance over different time periods: weekly change +0.92%, monthly -12.59%, and year-to-date -13.05%. The stock is currently trading with a volume of 69,609 shares.
6 What is the target level for Avalon Pharma?
According to automated analysis for Avalon Pharma: Short-term target (1-2 weeks): 95.00 SAR. Support level: 94.30 SAR. Resistance level: 101.55 SAR. Note: These are automated analytical levels and do not constitute investment advice.
Disclaimer
The information provided on this page is for educational and analytical purposes only and does not constitute investment advice or a recommendation to buy or sell. Past performance does not guarantee future results. All investments involve risk including loss of capital. Please consult a licensed financial advisor before making any investment decisions.
Automated analysis relies on historical data and technical indicators and may not reflect future market conditions.